Epstein Barr Virus: Paving the way for a vaccine using epidemiological and mathematical modelling approaches (360G-Wellcome-204419_Z_16_Z)
Epstein Barr Virus (EBV), a Lymphocryptovirus, permanently infects > 90% of humans. EBV causes > 90% of glandular fever, and is linked to 1% of global cancers. Why only a small fraction of infected individuals get cancer is poorly understood. No anti-EBV vaccines are currently licensed, although several candidates are in pre-clinical development. Lymphocryptoviruses have evolved with humans for many millennia. Our immune systems are likely to be well-adapted to EBV and vice versa. The impact of EBV infection through the human life-course is not known, nor is that of remaining permanently EBV-negative. As vaccines become available such questions will become increasingly important. Information derived from large cohorts and mathematical models of transmission will be critical before vaccines can be adopted. Prior to extensive vaccine investment a feasibility and scoping exercise of currently available data and resources is required. Our goals are: 1) Using pre-existing datasets, pilot assembly of a cohort of EBV-seronegative individuals for a life-course study; 2) Undertake systematic reviews to determine the strength of available evidence for different risk factors for EBV infection and EBV-associated cancers in different settings; 3) Develop a preliminary transmission dynamic model for vaccination, and identify knowledge gaps for a full model.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 88097 |
Applicant Surname | Stagg |
Approval Committee | Science Seeds Advisory Panel |
Award Date | 2016-08-15T00:00:00+00:00 |
Financial Year | 2015/16 |
Grant Programme: Title | Seed Award in Science |
Internal ID | 204419/Z/16/Z |
Lead Applicant | Dr Helen Stagg |
Partnership Value | 88097 |
Planned Dates: End Date | 2018-06-01T00:00:00+00:00 |
Planned Dates: Start Date | 2016-10-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |